JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (1): 63-66.doi: 10.6040/j.issn.1671-7554.0.2014.652

Previous Articles     Next Articles

Correlation between the expressions of Runx2 and Ezrin and postoperative metastasis in patients with stage IB non-small cell lung cancer

GAO Peng, SHEN Fangzhen, XIAO Wenjing, XIU Yuande, ZHOU Lingling   

  1. Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China
  • Received:2014-09-28 Revised:2014-12-01 Published:2015-01-10

PDF (PC)

76

Abstract: Objective To explore the expressions of runt-related transcription factor 2 (Runx2) and Ezrin gene in stage IB non-small cell lung cancer (NSCLC) and to investigate their relationship with postoperative recurrence and metastasis. Methods Forty resected IB stage NSCLC tissues were divided into the recurrence/metastasis group with postoperative recurrence (n=20) and control group without postoperative recurrence (n=20). Immunohistochemical method was used to detect the expressions of the Runx2 and Ezrin genes. The correlation between the gene expressions and disease free survival rate of patients with stage IB NSCLC were analyzed by Kaplan-Meier. Results The positive rates of Runx2 and Ezrin expressions in the recurrence/metastasis group were significantly higher than the control group (P=0.004, P=0.011). The positive expressions of Runx2 and Ezrin in the low differentiated tissues were higher than those in the moderate and high differentiated tissues (P=0.016, P=0.009). There was a positive correlation between Runx2 and Ezrin expression (r=0.646, P=0.001). The three-year disease free survival rate was lower in patients with Runx2 and Ezrin positive expressions (30.4% and 31.8%) than those with negative expressions (76.5% and 72.2%) (P=0.010, P=0.011). Conclusion Runx2 and Ezrin expressions are closely corelative to postoperative recurrence and metastasis in patients with stage IB NSCLC, and might be potential prognostic markers in stage IB NSCLC.

Key words: Runt-related transcription factor 2, Ezrin, Non-small cell lung cancer, Neoplasm metastasis

CLC Number: 

  • R734.2
[1] Chen W, Zheng R, Zhang S, et al. The incidences and mortalities of major cancers in China, 2009[J]. Chin J Cancer, 2013, 260(3):106-112.
[2] Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6):645-653.
[3] Hung JJ, Jeng WJ, Hsu WH, et al. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I nonsmall-cell lung cancer[J]. J Thorac Oncol, 2012, 7(7):1115-1123.
[4] Jiang W, Chen X, Xi J, et al. Selective mediastinal lymphadenectomy without intraoperative frozen section examinations for clinical stage I non-small-cell lung cancer:retrospective study of 403 cases[J]. World J Surg, 2013, 37(2):392-397.
[5] Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions[J]. J Clin Invest, 2009, 119(6):1429-1437.
[6] Sadikovic B, Thorner P, Chilton-MacNeill S, et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy [J]. BMC Cancer, 2010, 10:202.
[7] Onodera Y, Miki Y, Suzuki T, et al. Runx2 in human breast carcinoma:its potential roles in cancer progression[J]. Cancer Sci, 2010, 101(12):2670-2675.
[8] Yun SJ, Yoon HY, Bae SC, et al. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer[J]. Prostate Cancer and Prostatic Dis, 2012, 15(4):369-373.
[9] Pratap J, Imbalzano KM, Underwood JM, et al. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure:implications for breast cancer progression[J].Cancer Res, 2009, 69(17):6807-6814.
[10] Yang J, Zhao L, Tian W, et al. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma[J]. BMC Med Genomics, 2013, 6:56.
[11] Baniwal SK, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells:insights into invasiveness and bone metastasis. [J]. Mol Cancer, 2010, 9:258.
[12] Li H, Zhou RJ, Zhang GQ, et al. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer:a 5-year follow-up study[J]. Tumour Biol, 2013, 34(3):1807-1812.
[13] Hsu YL, Huang MS, Yang CJ, et al. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway[J]. J Biol Chem, 2011, 286(43):37335-37346.
[14] Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion[J]. Mol Cell Biol, 2005, 25(19):8581-8591.
[15] Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells[J]. J Biol Chem, 2004, 279(26):27764-27773.
[16] Gautreau A, Poullet P, Louvard D, et al. Ezrin, a plasma membranemicrofilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway[J]. Proc Natl Acad Sci U S A, 1999, 96(13):7300-7305.
[17] Rebillard A, Jouan-Lanhouet S, Jouan E, et al. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells[J]. Eur J Cancer, 2010, 46(8):1445-1455.
[18] Jin T, Jin J, Li X, et al. Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer[J]. BMC Cancer, 2014, 14:191.
[19] Zhang XQ, Chen GP, Wu T, et al. Expression and clinical significance of ezrin in non-small cell lung cancer[J].Clin Lung Cancer, 2012, 13(3):196-204.
[20] 闵大六,沈赞,林峰,等. Runx2和Ezrin基因在骨瘤组织中的表达及其临床意义[J].中国癌症杂志, 2012, 22(9):685-689. MIN Daliu, SHEN Zan, LIN Feng, et al. Clinical signi fi cances of Runx2 and Ezrin expressions in osteosarcoma[J]. China Oncology, 2012, 22(9):685-689.
[1] LI Jingyuan, SONG Ling, LIN Song, SONG Hui. Effects of carbon monoxide releasing molecule-3 on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 31-37.
[2] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[3] PENG Yue, FENG Zhen, XIE Hounai, WANG Hui, LI Meng, REN Wangang, LIU Tong, PENG Zhongmin. Surgical treatment for 61 patients with multiple lung lesions [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 42-46.
[4] WANG Lili, HUO Bin, WANG Lei, WANG Hao, HOU Dingkun, HUO Xiaodong, WANG Jinhuan, ZANG Li, CAO Qiang, CHAI Shude, WANG Haitao. Meta-analysis and system evaluation of 125I implantation in the treatment of early lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 76-83.
[5] YUAN Bing, LI Ranran, HAN Mingyong. Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 13-18.
[6] GAO Ang, WANG Shijiang, FU Zheng, SUN Xindong, YU Jinming, MENG Xue. A feasibility study for boost target delineation using 18F-FDG PET/CT in local advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 73-77.
[7] YANG Lu, LIU Yanguo, LI Jisheng, WANG Xiuwen. Effect of bufalin on chemosensitivity to cisplatin in non-small cell lung cancer and the underlying mechanisms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 6-11.
[8] YUAN Zhiping, MOU Huaping, CHEN Jialian, DENG Li. Expressions and significances of serum hepatic cancer-derived growth factor and vascular endothelial growth factor in patients with non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 63-66.
[9] ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, LIU Li. Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 95-98.
[10] WANG Xing-miao1， LI Meng-quan1， WANG Li-juan2， SU Jing1， HU Di1. Expressions of Caspase-3, OPN and Ezrin in invasive ductal  carcinoma of breasts and their clinical significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(4): 141-145.
[11] CHEN Qiang1,2, L Jiaju1, JING Tao2, LI Yujun3. Expressions of MMP-2/ CXCR4 and their clinical significance in renal clear cell carcinoma tissues [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(6): 107-.
[12] MENG Long, ZHANG Yangde, WANG Yibing. Clinical significance of vascular endothelial growth factor C and CD44v6 expressions in human non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(4): 83-86.
[13] LI Jun1,2, WANG Zhou1, LI Shuhai3, LI Yu4. Investigation of expression of ABH and Lewis blood group antigens and their relationship to the biological behaviors of primary lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(4): 124-129.
[14] . Metastases associated with proteins in breast cancer by proteomics [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(7): 61-64.
[15] LONG Chengfeng， LIN Dianjie， CUI Jiyun， WAN Yunyan
. Correlation between galectin3 and lymphatic metastasis and
pleural metastasis in lung adenocarcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 72-75.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd